![James Porter](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
James Porter
Amministratore Delegato presso
NUVALENT, INC.
Patrimonio netto: 36 M $ in data 31/05/2026
Profilo
James R.
Porter is President, Chief Executive Officer & Director at Nuvalent, Inc. since 2020, with employment at the company starting in 2017.
Formerly, Dr. Porter was Vice President-Product Development at Infinity Pharmaceuticals, Inc. from 2002 to 2016.
Education includes a doctorate from Boston College.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 08/06/2026 | 324.879 ( 0,44% ) | 36 M $ | 31/05/2026 |
Posizioni attive di James Porter
| Società | Posizione | Inizio |
|---|---|---|
| NUVALENT, INC. | Amministratore Delegato | 01/01/2017 |
Precedenti posizioni note di James Porter
| Società | Posizione | Fine |
|---|---|---|
| INFINITY PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/12/2016 |
Formazione di James Porter
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
44
Relazioni di 1° grado
4
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 4 |
|---|---|
College of the Holy Cross (Massachusetts)
 College of the Holy Cross (Massachusetts) Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Infinity Pharmaceuticals, Inc.
 Infinity Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops medicines for the treatment of cancer | Health Technology |
Boston College
 Boston College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Nuvalent, Inc.
 Nuvalent, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of targeted therapies for patients with cancer | Health Technology |
